CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech which has worked hard but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.
In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.
CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.
While CYDY happens to be dawdling, market opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV are actually closing.
I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last several shares. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out all of the following prediction:
Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire job interview that I came away with a bad impression of the business.
Irony of irony, my poor viewpoint of the company has grown steadily, though the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.
What manner of stock is it that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.
CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back during 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and linked intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) along with the first new drug application endorsement ($five million), as well as royalty payments of 5 % of net sales upon commercialization.
Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

Instead of having a pipeline with numerous therapies and many indications, it’s this single treatments and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.
The opening banner of its on the site of its (below) shows an active business with diverse interests albeit focused on leronlimab, several illness sorts, multiple presentations and multiple publications.
Can all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the really start of the interest of mine in this organization. Judging by way of the multiples of a huge number of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.
CytoDyn is a traditional battleground, or some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News